1
haematologica | 2021; 106(3) ABOUT THE COVER 655 Images from the Haematologica atlas of hematologic cytology: Chediak-Higashi syndrome Ana P. De Azambuja 1 and Carlo L. Balduini 2 1 Universitade Federal do Paranà, Curitiba, Brazil and 2 Ferrata-Storti Foundation, Pavia, Italy E-mail: CARLO BALDUINI - [email protected] doi:10.3324/haematol.2020.278224 C hediak-Higashi syndrome (CHS) is a complex inherited disorder caused by homozygous or compound heterozy- gous mutation in the lysosomal trafficking regulator gene LYST on chromosome 1q42. A peculiar feature of this condition is the presence of typical, giant granules in leukocyte cytoplasm. Pseudo Chédiak-Higashi granules can occasionally be observed in myeloid elements in a few acquired hematologic disorders such as acute leukemia, myelopro- liferative and myelodysplastic syndromes. However, the abnormal granulation in acquired conditions affects a few cells as opposed to generalized involvement of white blood cells in CHS. Giant granules are particularly evident and numerous in neutrophils (A-E). In these cells, they derive from the fusion of azurophilic granules in early precursors, with subse- quent incorporation of some specific granules in the myelocyte stage. The mature neutrophils therefore contain both the abnormal azurophilc granules and a variable number of normal specific granules. Concentration of digestive enzymes in giant granules is reduced and this results in defective bactericidal function. Giant granules are observed also in eosinophils (F), basophils, lymphocytes (E, G, H) and monocytes (I). In mononuclear cells the number of granules is usually small. Note the different colorability of the granules in the polymorphonuclear cells and in the mononuclear cells, which reflects their different content. CHS may also show abnormalities of nuclear lobation in granulocytes as seen in A, D and F. 1 References 1. de Azambuja AP, Balduini CL. Haematologica. 2020; 105(Suppl 1):S225-226.

Images from the Haematologica atlas of hematologic

  • Upload
    others

  • View
    5

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Images from the Haematologica atlas of hematologic

haematologica | 2021; 106(3)

ABOUT THE COVER

655

Images from the Haematologica atlas of hematologic cytology: Chediak-Higashi syndromeAna P. De Azambuja1 and Carlo L. Balduini2

1Universitade Federal do Paranà, Curitiba, Brazil and 2Ferrata-Storti Foundation, Pavia, Italy

E-mail: CARLO BALDUINI - [email protected]

doi:10.3324/haematol.2020.278224

Chediak-Higashi syndrome (CHS) is a complex inherited disorder caused by homozygous or compound heterozy-gous mutation in the lysosomal trafficking regulator gene LYST on chromosome 1q42. A peculiar feature of thiscondition is the presence of typical, giant granules in leukocyte cytoplasm. Pseudo Chédiak-Higashi granules can

occasionally be observed in myeloid elements in a few acquired hematologic disorders such as acute leukemia, myelopro-liferative and myelodysplastic syndromes. However, the abnormal granulation in acquired conditions affects a few cellsas opposed to generalized involvement of white blood cells in CHS. Giant granules are particularly evident and numerousin neutrophils (A-E). In these cells, they derive from the fusion of azurophilic granules in early precursors, with subse-quent incorporation of some specific granules in the myelocyte stage. The mature neutrophils therefore contain both theabnormal azurophilc granules and a variable number of normal specific granules. Concentration of digestive enzymes ingiant granules is reduced and this results in defective bactericidal function. Giant granules are observed also in eosinophils(F), basophils, lymphocytes (E, G, H) and monocytes (I). In mononuclear cells the number of granules is usually small.Note the different colorability of the granules in the polymorphonuclear cells and in the mononuclear cells, which reflectstheir different content. CHS may also show abnormalities of nuclear lobation in granulocytes as seen in A, D and F.1

References

1. de Azambuja AP, Balduini CL. Haematologica. 2020; 105(Suppl 1):S225-226.